Allergan gains US FDA nod for Botox in overactive bladder

Allergan racked up another indication for Botox (onabotulinumtoxinA) – known mostly for its antiwrinkle capabilities – this time to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency and frequency but are unable to use or have had an inadequate response to anticholinergics.

More from Dermatological

More from Therapeutic Category